Italia markets closed

OncoCyte Corporation (0KCC.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
3,6250+1,3099 (+56,58%)
Alla chiusura: 06:34PM GMT
Schermo intero
Chiusura precedente2,3151
Denaro0,0000 x N/D
Lettera0,0000 x N/D
Min-Max giorno0,0000 - 0,0000
Intervallo di 52 settimane
Media Volume159
Beta (5 anni mensile)1,57
Rapporto PE (ttm)N/D
EPS (ttm)-0,7710
Prossima data utili09 nov 2023
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    VitaGraft Kidney Expands Utility in Recurrent Primary Disease Patients

    - Blood-based test differentiates between ABMR and IgAN, enabling faster and more effective treatment- Improved utility over standard of care tests- Paper published in peer-reviewed journal IRVINE, Calif., July 25, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced the publication of new data demonstrating VitaGraft Kidney’s novel ability to help physicians treat kidney transplant patients more precisely, quickly, and effectively. The te

  • GlobeNewswire

    Oncocyte Announces 1-For-20 Reverse Stock Split

    IRVINE, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX) (the “Company”), a precision diagnostics company, announced today that the Company will implement a 1-for-20 reverse stock split of the outstanding shares of its common stock. The reverse stock split will be effective at 5:00 p.m. Pacific time on July 24, 2023, and the Company’s common stock will begin to trade on a post-split basis at the market open on July 25, 2023, under the Company’s existing trading symbol

  • GlobeNewswire

    Oncocyte Begins Manufacturing Transplant Blood Test

    Over 1 million annual testing opportunities in US Q4 targeted for early access launch IRVINE, Calif., June 27, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that it has begun the manufacturing process for the distributable version of its patented transplant technology. A method of checking for signs of graft damage in transplant recipients, the assay measures levels of donor derived cell-free DNA (dd-cfDNA) in the blood. Early acces